Testing a potential drug for use in T-cell lymphomas

A molecule may have anticancer effects towards T-cell lymphomas, if this is found to be true, a clinical trial could be done to see its benefits in patients.

T-cell lymphomas are a group of blood cancers from white blood cells of the immune system. Recently it has been shown that some T-cell lymphomas develop from a specific cell called T-follicular helper (Tfh) cells. These specific cancers are now termed Tfh lymphoma.

Targetting Tfh lymphomas with antibodies

Tfh lymphoma cancer cells have abnormally large amounts of a protein called ICOS, needed for cellular growth and survival. Anti-ICOS antibody is a molecule that blocks the action of ICOS. It could stop the cancer cell from growing and surviving, improving clinical outcomes for patients.

This project aims to study the effect of anti-ICOS antibodies on Tfh lymphoma cancer cells. This will generate the essential data and information needed to propose a future clinical trial to see the effects of the drug in patients.

This award of £9,000 was awarded to Dr Matthew Ahearne at the Department of Cancer Studies and Molecular Medicine at the University of Leicester and is part of Hope’s funding of priority research in the new Leicester Centre of Excellence.

More information (links open in a new tab):

T-cell lymphomas